NCT03150693
|
Phase III |
Rituximab
Doxorubicin
Mercaptopurine
Methotrexate
Cyclophosphamide + Cytarabine
Thioguanine
Allopurinol
Daunorubicin
Dexamethasone
Vincristine
inotuzumab ozogamicin
|
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
Recruiting |
NCT02456857
|
Phase II |
Bevacizumab
Doxorubicin
Temsirolimus
|
Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy |
Recruiting |
NCT03007147
|
Phase III |
Pegaspargase
Methotrexate
Leucovorin
Cytarabine
Mercaptopurine
Thioguanine
Vincristine
Cyclophosphamide
Imatinib
Ifosfamide
dexrazoxane
Daunorubicin
Dexamethasone
Methylprednisolone
Etoposide
Prednisolone
Doxorubicin
|
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Recruiting |
NCT02446600
|
Phase III |
Paclitaxel
Doxorubicin
Gemcitabine
Carboplatin
Olaparib
Cediranib
|
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT01857934
|
Phase II |
Doxorubicin
Sargramostim
Aldesleukin
Vincristine
Filgrastim
Tretinoin
Levetiracetam
Cisplatin + Etoposide
Hu14.18K322A
Busulfan + Melphalan
Cyclophosphamide + Topotecan
|
Therapy for Children With Advanced Stage Neuroblastoma |
Recruiting |
NCT03020030
|
Phase III |
Nelarabine
dexrazoxane
Asparaginase
Vincristine
Cyclophosphamide
Cytarabine
Mercaptopurine
Pegaspargase
Methotrexate
Etoposide
Doxorubicin
Dexamethasone
Prednisone
Dasatinib
Leucovorin
|
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents |
Recruiting |
NCT02648477
|
Phase II |
Bevacizumab
Letrozole
Anastrozole
Exemestane
Doxorubicin
|
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer |
Recruiting |
NCT02460991
|
Phase I |
Sorafenib
Doxorubicin
|
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma |
Terminated |
NCT02606305
|
Phase I |
Bevacizumab
Carboplatin
Doxorubicin
Mirvetuximab Soravtansine
|
Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer |
Recruiting |
NCT02483247
|
Phase Ib/II |
Paclitaxel
Doxorubicin
Capecitabine
Nivolumab
Sunitinib
Pembrolizumab
BBI503
|
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer |
Active, not recruiting |
NCT02419495
|
Phase I |
Cyclophosphamide
Pemetrexed
Eribulin
Selinexor
Carboplatin
Paclitaxel
Topotecan
Dexamethasone
Doxorubicin
|
Selinexor in Combination With Standard Chemotherapy |
Recruiting |
NCT03126916
|
Phase III |
Doxorubicin
131I-MIBG
Sargramostim
Etoposide
Melphalan
Busulfan
Isotretinoin
Vincristine
Cisplatin
Cyclophosphamide
Thiotepa
Crizotinib
dexrazoxane
Carboplatin
Aldesleukin
Topotecan
Dinutuximab
|
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma |
Recruiting |
NCT02312245
|
Phase II |
Topotecan
Doxorubicin
Paclitaxel
Gemcitabine
|
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
NCT01459380
|
Phase I |
Carboplatin
Doxorubicin
Veliparib
Bevacizumab
|
Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
NCT03023046
|
Phase II |
Rituximab
Doxorubicin
Etoposide
Imatinib
Dasatinib
Cyclophosphamide
Prednisone
Vincristine
|
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Recruiting |
NCT01375699
|
Phase I |
Doxorubicin
|
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers |
Completed |
NCT02331251
|
Phase Ib/II |
Vinorelbine
Pembrolizumab
Irinotecan
Doxorubicin
Gemcitabine
Docetaxel
nab-paclitaxel
|
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
Terminated |
NCT03145558
|
Phase II |
Doxorubicin
tirapazamine
|
TATE Versus TACE in Intermediate Stage HCC (TATE) |
Recruiting |
NCT02419755
|
Phase II |
Cytarabine
Mercaptopurine
Methotrexate
Pegaspargase
Vorinostat
Doxorubicin
Bortezomib
Dexamethasone
Mitoxantrone
Prednisone
|
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies |
Terminated |
NCT01015833
|
Phase III |
Doxorubicin
Sorafenib
|
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer |
Active, not recruiting |
NCT03117751
|
Phase II |
Cyclophosphamide
Vincristine
Idarubicin
Blinatumomab
Doxorubicin
Clofarabine
Vorinostat
Ruxolitinib
Prednisone
Bortezomib
Etoposide
Dasatinib
Daunorubicin
Dexamethasone
Rituximab
Methotrexate
Cytarabine
Mercaptopurine
Pegaspargase
|
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
Recruiting |
NCT02112916
|
Phase III |
Cyclophosphamide
Vincristine
Ifosfamide
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Leucovorin
Daunorubicin
Dexamethasone
Bortezomib
Etoposide
Doxorubicin
|
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
Suspended |
NCT02580058
|
Phase III |
Doxorubicin
Avelumab
|
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer |
Active, not recruiting |
NCT02192021
|
Phase I |
Doxorubicin
|
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) |
Recruiting |
NCT02049905
|
Phase III |
Dacarbazine
Doxorubicin
Ifosfamide
Pazopanib
Aldoxorubicin
Gemcitabine + Docetaxel
|
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas |
Completed |
NCT03197935
|
Phase III |
Pegfilgrastim
Doxorubicin
Atezolizumab
Filgrastim
nab-paclitaxel
Cyclophosphamide
|
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) |
Active, not recruiting |
NCT01523977
|
Phase I |
Prednisone
Everolimus
Vincristine
Doxorubicin
Pegaspargase
|
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL |
Active, not recruiting |
NCT02788201
|
Phase II |
Erlotinib
Thiotepa
Imatinib
Dacarbazine
Arsenic trioxide
Idarubicin
Mitomycin C
Thioguanine
Mercaptopurine
Methotrexate
Cladribine
epirubicin
Gemcitabine
Doxorubicin
Bleomycin
Etoposide
Gefitinib
Daunorubicin
Lomustine
Sorafenib
Sunitinib
Ifosfamide
Asparaginase
Ixabepilone
Abiraterone
Azacitidine
Ruxolitinib
Decitabine
Axitinib
Estramustine
Floxuridine
Lapatinib
Carmustine
Fludarabine
Nilotinib
Cisplatin
Vismodegib
Vandetanib
Melphalan
Busulfan
Carboplatin
Toremifine
Crizotinib
Dactinomycin
Temsirolimus
Vorinostat
romidepsin
Fluorouracil
Irinotecan
Bortezomib
Tamoxifen
Topotecan
Chlorambucil
Pentostatin
Eribulin
Carfilzomib
Vemurafenib
Hydroxyurea
Exemestane
Vincristine
Dasatinib
Mitoxantrone
Vinblastine
Cytarabine
Tretinoin
Clofarabine
Teniposide
Docetaxel
Pazopanib
Oxaliplatin
Streptozocin
Paclitaxel
Bendamustine
Mechlorethamine
Mitotane
|
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Recruiting |
NCT03571321
|
Phase I |
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Ruxolitinib
Cyclophosphamide
Dexamethasone
Vincristine
Rituximab
Doxorubicin
|
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
Not yet recruiting |
NCT02494713
|
Phase II |
Degarelix
Estramustine
Docetaxel
Doxorubicin
Ketoconazole
|
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer |
Terminated |
NCT02094872
|
Phase II |
Doxorubicin
|
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic |
Active, not recruiting |
NCT00074490
|
Phase II |
Cyclophosphamide
Cyclosporine
Rituximab
Doxorubicin
Etoposide
Filgrastim
Vincristine
Fludarabine
|
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers |
Terminated |
NCT01655693
|
Phase III |
Doxorubicin
|
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) |
Active, not recruiting |
NCT02451943
|
Phase III |
Olaratumab
Doxorubicin
|
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma |
Active, not recruiting |
NCT03056599
|
|
Gemcitabine
Interferon alfa-2b
Doxorubicin
Pembrolizumab
Eribulin
interferon gamma
Ipilimumab
Trabectedin
Aldesleukin
Bortezomib
Docetaxel
|
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma |
Recruiting |
NCT01319981
|
Phase II |
Pegfilgrastim
Imatinib
Filgrastim
Rituximab
Doxorubicin
Dexamethasone
Vincristine
Cyclophosphamide
|
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT01750073
|
Phase II |
Doxorubicin
Trastuzumab
Cyclophosphamide + Paclitaxel
|
Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer |
Recruiting |
NCT00549848
|
Phase III |
Vincristine + Pegaspargase + Daunorubicin
Cytarabine
Mercaptopurine
Thioguanine
Clofarabine + Etoposide + Cyclophosphamide
Methotrexate
Dasatinib
Doxorubicin
Dexamethasone
|
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT03004287
|
Phase II |
Melphalan
Carfilzomib
Cisplatin
Cyclophosphamide
Lenalidomide
Dexamethasone
Daratumumab
Bortezomib
Etoposide
Doxorubicin
Thalidomide
|
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy |
Recruiting |
NCT03319901
|
Phase I |
Cytarabine
Mercaptopurine
Methotrexate
Cyclophosphamide
Venetoclax
Doxorubicin
Etoposide
Vincristine
|
Venetoclax and Chemotherapy In ALL |
Recruiting |
NCT03517449
|
Phase III |
Lenvatinib + Pembrolizumab
Paclitaxel
Doxorubicin
|
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) |
Recruiting |
NCT01815294
|
Phase I |
Doxorubicin
Doxil
|
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer |
Completed |
NCT00980460
|
Phase III |
Irinotecan + Temsirolimus + Vincristine
Cisplatin + Fluorouracil + Vincristine
Doxorubicin
|
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer |
Active, not recruiting |
NCT02502266
|
Phase II |
Topotecan
Paclitaxel
Doxorubicin
Olaparib
Cediranib
|
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
NCT02677116
|
Phase I |
Doxorubicin
Ifosfamide
Irinotecan + Vincristine
Olaratumab
|
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer |
Active, not recruiting |
NCT02349958
|
Phase II |
Mitomycin C
Cisplatin
Doxorubicin
|
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy |
Unknown status |